We show that, (1) HFSD administered over a 12-week period is sufficient to cause splenomegaly in mice, (2) combined exercise and genistein treatment may reverse splenic enlargement associated with HFSD, and (3) the reduction in splenomegaly with combined exercise and genistein treatment directly correlates with reductions in plasma glucose and IL-6 levels. The gene discussed is IL6; the disease is Splenomegaly.